Quantum-Si Added to the Nasdaq Biotechnology Index
Quantum-Si (Nasdaq: QSI) has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI) as part of its annual reconstitution, effective December 20, 2021. The Nasdaq Biotechnology Index tracks the performance of biotechnology and pharmaceutical securities based on specific eligibility criteria such as market capitalization and trading volume. Quantum-Si specializes in protein sequencing technology, aiming to enhance drug discovery and diagnostics through its innovative semiconductor chip designed for single molecule sequencing.
- Inclusion in the Nasdaq Biotechnology Index enhances Quantum-Si's visibility and credibility among investors.
- The company focuses on cutting-edge protein sequencing technology, which is crucial for advancing drug discovery.
- The press release contains forward-looking statements, indicating risks and uncertainties that could impact the company's performance.
- The company faces challenges such as competition and the ability to secure future financing for development.
Launched in 1993, the Nasdaq Biotechnology Index is a modified market-cap weighted index designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). Companies in the Nasdaq Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. Nasdaq selects constituents once annually in December.
For more information about the Nasdaq Biotechnology Index, please visit https://indexes.nasdaqomx.com/Index/Overview/NBI.
About
Founded by Dr.
Forward Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's shares of Class A common stock on
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005887/en/
Investor Contacts
(617) 877-9641
ir@quantum-si.com
Media Contact
(203) 682-8380
QSI-PR@westwicke.com
Source:
FAQ
When was Quantum-Si added to the Nasdaq Biotechnology Index?
What is the significance of Quantum-Si joining the Nasdaq Biotechnology Index?
What technology does Quantum-Si specialize in?